Brief: Adial Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
23/08/2023 13:31
Aug 23 (Reuters) -
* ADIAL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ
LISTING
REQUIREMENTS
Source text for Eikon: ID:nGNXDVCNM
Further company coverage: ADIL.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)